DocDollars

Xeris Pharmaceuticals, Inc.

IL · United States · Reporting entity ID 100000781817

Total reported 2019–2025
$11.6M
#450 of 2,960 reporting companies — 0% of all reported industry payments
$5.32M in general payments across 128,324 records, plus $6.27M in research funding across 263 records.

How it breaks down

General payments $5,317,085
Research funding $6,265,464

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Xeris Pharmaceuticals, Inc. reported $11.6M to US doctors and teaching hospitals from 2019 to 2025, ranking #450 of 2,960 reporting companies. 54% of that was research funding and 46% general payments such as consulting, speaking, food and travel. 128,324 general payment records and 263 research records were filed.

Common questions about Xeris Pharmaceuticals, Inc.

How much has Xeris Pharmaceuticals, Inc. paid US doctors?

Xeris Pharmaceuticals, Inc. reported $11,582,549 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $5,317,085 in general payments, $6,265,464 in research funding.

How does Xeris Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #450 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Xeris Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.